Future multibillion-dollar obesity market will be dominated by Novo and Lilly, bank predicts

Players are beginning to position themselves as a very lucrative market for weight-loss drugs matures, but Morgan Stanley believes the two rivals Novo Nordisk and Eli Lilly will take almost half.

Photo: Novo Nordisk / PR

Eli Lilly, Amgen, and a number of other companies are seeking to challenge Novo Nordisk on the obesity market, which is facing a demand boom in coming years, investment bank Morgan Stanley assesses according to media Financial Times.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs